Evidence map›Paper›PMID 28770228›Full record

ArticleBioMed research international2017

MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study.

Wiktor Kuliczkowski, Marek Radomski, Mariusz Gąsior, Joanna Urbaniak, Jacek Kaczmarski, Andrzej Mysiak, Marta Negrusz-Kawecka, Iwona Bil-Lula

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Article
  3. Cell journal · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Wiktor KuliczkowskiDepartment and Clinic of Cardiology, Wroclaw Medical University, Borowska Street 213, 50-556 Wroclaw, Poland.
Marek RadomskiDepartment of Pharmacology, College of Medicine, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK, Canada S7N 5E5.
Mariusz Gąsior3rd Chair and Department of Cardiology, Silesian Center for Heart Diseases, M. Curie-Sklodowskiej Street 9, 41-800 Zabrze, Poland.
Joanna UrbaniakDepartment of Laboratory Diagnostics, Lower Silesian Oncology Center in Wroclaw, Hirszfelda Street 12, 53-413 Wroclaw, Poland.
Jacek Kaczmarski3rd Chair and Department of Cardiology, Silesian Center for Heart Diseases, M. Curie-Sklodowskiej Street 9, 41-800 Zabrze, Poland.
Andrzej MysiakDepartment and Clinic of Cardiology, Wroclaw Medical University, Borowska Street 213, 50-556 Wroclaw, Poland.
Marta Negrusz-KaweckaDepartment and Clinic of Cardiology, Wroclaw Medical University, Borowska Street 213, 50-556 Wroclaw, Poland.
Iwona Bil-LulaDepartment of Clinical Chemistry, Wroclaw Medical University, Borowska Street 211A, 50-556 Wroclaw, Poland.ORCID 0000-0002-2769-0166
Wroclaw Medical University · PLSilesian Center for Heart Disease · PLLublin Oncology Center · PLUniversity of Saskatchewan · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh on-aspirin treatment platelets reactivity (HPR) is a significant problem in long-term secondary prevention of cardiovascular events. We hypothesize that imbalance between platelets MMPs/TIMPs results in cardiovascular disorders. We also explored whether chronically elevated blood glucose affects MMP-2/TIMP-4 release from platelets. MATERIALS AND

methodsSeventy patients with stable coronary artery disease, supplemented with aspirin, participated in this pilot study. The presence of HPR and/or diabetes mellitus was considered as the differentiating factor. Light aggregometry, impedance aggregometry, and ELISA tests for TXB2, MMP-2, MMP-9, and TIMP-4 were performed in serum, plasma, platelet-rich plasma, and platelets-poor plasma, as appropriate.

resultsAspirin-HPR did not affect plasma MMP-2, MMP-9, and TIMP-4. Arachidonic acid-induced aggregation of platelets from aspirin-HPR patients did not lead to increased release of MMP-2, MMP-9, and TIMP-4. Studying patients at the lowest TXB2 serum concentration quartile revealed that high concentration of plasma TIMP-4 and TIMP-4 negatively correlated with TXB2 and platelet aggregation. Diabetics showed an increased plasma MMP-2 as well as an increased MMP-2 in supernatants after platelet aggregation. However, diabetes mellitus did not affect MMP-9 and TIMP-4.

conclusionAspirin-HPR did not affect the translocation and release of MMPs and TIMP-4 from platelets. TIMP-4 may serve as a marker of TXA2-mediated platelet aggregation. Chronically elevated plasma glucose increases plasma MMP-2, and HPR potentiates this phenomenon.

Indexed as

AspirinBlood PlateletsCoronary Artery DiseaseDiabetes MellitusFemaleHumansMaleMatrix Metalloproteinase 2Matrix Metalloproteinase 9Middle AgedPilot ProjectsPlatelet AggregationPlatelet Aggregation InhibitorsPlatelet Function TestsPlatelet-Rich PlasmaSecondary PreventionAspirinMatrix Metalloproteinase 2Matrix Metalloproteinase 9Platelet Aggregation InhibitorsTIMP1 protein, humanTissue Inhibitor of Metalloproteinase-1

Identifiers

PMID28770228
PMCPMC5523290
OpenAlexW2735703545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.